Core Viewpoint - Treatment.com AI Inc. is initiating a non-brokered private placement to raise up to C$3 million due to strong interest from investors, offering special warrants and units at C$0.50 each [1][5]. Group 1: Offering Details - The offering consists of special warrants and units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to acquire one share at C$0.75 for 12 months following issuance [1]. - Special warrants will automatically convert into units on the earlier of the filing of a prospectus supplement or four months and one day after issuance [2]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized for working capital purposes [5]. Group 3: Conditions and Fees - The offering is expected to close by August 18, 2025, and is subject to necessary approvals, including from the Canadian Securities Exchange [5]. - The company may pay a finder's fee of up to 8% of gross proceeds and issue broker warrants equal to 8% of the number of special warrants and/or units sold [4]. Group 4: Company Overview - Treatment.com AI is focused on improving healthcare through AI and best clinical practices, with a comprehensive healthcare AI engine known as the Global Library of Medicine (GLM) [7]. - The GLM provides clinical information and support to healthcare professionals, helping to reduce administrative burdens and improve patient care [7].

Not for distribution to United States newswire services or for release publication, distribution, or dissemination directly, or indirectly, in whole or in part, in or into the United States.Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (the “Company” or “Treatment”) (CSE: TRUE; OTC: TREIF; 939: FRA) is pleased to announce that due to strong inbound interest from new and existing investors, it is undertaking a non-brokered private placement of up to C$3 million of a com ...

Yduqs Participações (YDUQ3) Update / Briefing July 25, 2025 08:15 AM ET Speaker0Mr. Eduardo Parenci. Please, Mr. Parenci, you may proceed. Good morning, everyone.I hope you are all doing well as you saw yesterday and today. In the communication media and reports of various analysts, we are announcing a transition at Itux. I am passing the baton to Olsen. I think transition is extremely positive for the company. From time to time, companies change leadership more or less.I'm a CEO for sixteen years. I'm a bo ...

The "Warren Buffett of Britain" dumped Buffett's actual No. 1 holding in favor a stock with the legs to run higher. The flow of information is constant and sometimes overwhelming on Wall Street. Trying to interpret an onslaught of earnings reports and monthly economic data releases each quarter can easily allow something of importance to go unnoticed. For example, May 15 marked the deadline for institutional investors with at least $100 million in assets under management to file Form 13F with the Securities ...

SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (Nasdaq: INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effec ...

SAN DIEGO, July 23, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations tha ...

CANTON, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that second quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, August 7th. Management will host a conference call at 5:00 p.m. Eastern Time on August 7th to dis ...

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a further transition to intermed ...

Participation certificates (Partizipationsscheine) with a nominal value of CHF 0.001 each will replace the non-voting equity securities (Genussscheine). Reduction of the nominal value of the bearer shares (Inhaberaktien) from CHF 1 to CHF 0.001 in line with the nominal value of the new participation certificates.Participation certificates are economically equivalent to Genussscheine and will be listed on the SIX Swiss Exchange.Discontinuation of printed dividend vouchers and a further transition to intermed ...

PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its second quarter financial results and business updates after the market closes on Tuesday, August 5, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio’s presentation ...